Gene Therapy to Target CD19 for Oncology and Immunology is under clinical development by Shanghai GeneChem and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target CD19 for Oncology and Immunology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target CD19 for Oncology and Immunology overview
Gene therapy is under development for the treatment of systemic lupus erythematosus. The drug candidate is administered through parenteral (infusion) route. It is an engineered lentiviral vector transduced CAR T cell contains anti CD19 and 4-1BB as co-stimulator. The drug candidate acts by targeting CD19. It was also under development for relapsed and refractory CD19 positive B-cell acute lymphocytic leukemia (B-ALL), B-cell non-Hodgkin lymphoma (B-NHL), chronic lymphocytic leukemia (CLL).
For a complete picture of Gene Therapy to Target CD19 for Oncology and Immunology’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
